



# odontoprev

## Webcast

### 4Q25

# New growth cycle and value innovation



IGC-NM B3

SMLL B3

IDIVERSA B3

IGPTWB3

IDIV B3

ISEB3



Prime



# Disclaimer



The information contained herein has been prepared by Odontoprev S.A. (“Odontoprev” or the “Company”) and this material does not constitute offering material in whole or part.

This material has been prepared solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities and should not be treated as giving investment advice. It is not targeted to the specific investment objectives financial situation or particular needs of any recipient. No representation or warranty either express or implied is made as to the accuracy completeness or reliability of the information contained herein. It should not be regarded by recipients as a substitute for the exercise of their own judgment. Any opinions expressed in this material are subject to change without notice and OdontoPrev is not under obligation to update or keep current the information contained herein. The Company their respective affiliates. agents. directors. partners and employees accept no liability whatsoever for any loss or damage of any kind arising out of the use of all or any part of this material.


This material is intended solely for the use of persons who are market counterparties of intermediate customers (as detailed in the FSA Rules) and is only available to such persons. The information contained herein does not apply to and should not be relied upon by private customers.

You should consult your own legal regulatory tax business. Investment. financial and accounting advisers to the extent that you deem necessary, and you must make your own investment hedging or trading decision based upon your own judgment and advice from such advisers as you deem necessary and not upon any view expressed in this material.

The information contained in this presentation concerning market estimates. The Brazilian dental and healthcare industry and our participation in it as well as our position in relation to our competitors was obtained from established public sources including the ANS. the Ministry of Health (Ministério da Saúde) and other market sources. We consider these sources to be reliable, but we have not independently verified the competitive position market share production and market size market growth data and other market estimates and therefore cannot provide any assurances regarding the accuracy and completeness of the information contained therein.


## Net revenue and average ticket

R\$ million/member/month



## Bradesco Dental: SME net additions


Thousand lives



## Dental care ratio and Adjusted EBITDA margin


% NOR

Dental care ratio



## Cash Flow 2025

R\$ million



\*Includes dividends, interest on capital, and share buybacks.



# Medical and dental plans: different penetration profiles

Million members


## Medical plans

+2,648 thousand members




## Dental plans: + 15.5 million members since 2014

+15,500 thousand members




# Odontoprev's revenue is approximately 3x higher than other dental plan providers

2025



5 Source: <sup>1</sup>Odontoprev and ANS; <sup>2</sup>Payments; <sup>3</sup>OCT24-SEP25; <sup>4</sup>Includes R\$73 million in other revenues



# Value innovation: SME and Individual plans revenue CAGR of 12% since 2014




R\$ million

● 2014 ● 2025


Average Ticket  
(R\$/member/month)

SME and Individual:



# Composition evolution net revenue by segment


R\$ million and % NOR




# Annual Average ticket, Average cost of services and Dental care ratio by segment




## Corporate



## SME



## Individual Plans



— Average ticket (R\$/member/month)

■ Dental care ratio (%)

- - Average cost of services (R\$/member/month)

# Contribution margin: non-corporate plans increased the margin over the last 11 years




R\$ million

● 2014 ● 2025

Contribution margin (R\$ million) Corporate:

SME and Individual:




<sup>10</sup> Contribution Margin = NOR – Cost of Services – Selling expenses

# SG&A and Allowance for doubtful receivables as % NOR




% NOR

Administrative expenses   Selling expenses   Allowance for doubtful receivables




# Dental care ratio and Adjusted EBITDA margin since the 2006 IPO

% NOR




# Financial income and Net cash since 2022

R\$ million



# Net income has grown at a CAGR of 20% since the IPO in 2006

R\$ million




# CAPEX: Technology represents the bulk of investments

R\$ million



- The annual CAPEX level demonstrates the Company's digital initiatives.




15 <sup>1</sup> Development of systems, acquisition and licensing of software and computer equipment

# Shareholder remuneration since 2022: 95% average payout ratio

R\$ million | Accrual basis




Net income Dividends IOC Share buyback



Payout: 2022 91% 2023 95% 2024 97% 2025 83%


# Global shareholder structure: investors from more than 30 countries

January, 2026



Total Capital

545,825,286 shares



Free float

251,735,971 shares

# Awards and Recognitions in 2025



#19 in the world and #1 in Brazil in TIME Magazine's global ranking



1st place in the Dental Plans category, for 12 years in a row

